What You Should KnowHealthcare data and AI platform H1 announced a strategic partnership with global pharmaceutical leader Novo Nordisk to modernize clinical trial development. Under the agreement, H1 will acquire rights to further advance StudyHub, Novo Nordisk’s proprietary digital and AI-enabled platform for clinical trial execution. The collaboration combines H1’s global Doctor Graph and AI-ready datasets with Novo Nordisk’s clinical trial operations to optimize protocol design, site selection, and patient enrollment. Bypassing Site Selection Bottlenecks: H1 Acquires Rights to Novo Nordisk’s StudyHubH1 and Novo Nordisk have entered a strategic partnership to accelerate clinical trial execution and streamline drug development workflows. Under the agreement, Novo Nordisk will integrate H1’s healthcare data platform into its clinical operations, while H1 will acquire the commercial rights to further develop and scale StudyHub, Novo Nordisk’s proprietary digital trial platform.